Submit your Article

Every year brings hopeful news about brain disease. Scientists discover drugs that remove toxic proteins. Experimental treatments rescue neurons in animals. Brain scans now reveal damage to extraordinary precision. From the outside, it feels as if cures for Alzheimer’s disease and Parkinson’s disease must already exist somewhere, waiting only to reach patients. Yet inside clinics, the conversation sounds very different.

Doctors can help reduce tremors, improve mobility, and temporarily slow memory decline. But stopping the disease itself remains rare. Families struggle to understand this contradiction. If science is advancing so rapidly, why does the illness continue to progress? This question has quietly become one of the central challenges of modern medicine.

Across all areas of drug development, treatments for brain disorders fail more often than therapies for heart disease, infections, or cancer. Large analyses of pharmaceutical pipelines published in Nature Biotechnology, Biostatistics, and BIO industry reports show that only about 6 to 8 percent of neurological drugs entering clinical trials eventually reach approval. Most fail during Phase II clinical trials; the stage designed to prove that treatment improves human life rather than laboratory biology. In the laboratory, disease looks solvable. In real people, it behaves differently.

When the brain looks better, but the person does not

For decades, Alzheimer’s research focused on amyloid plaques and sticky protein deposits in the brain. The logic seemed simple: remove the plaques and the disease should slow. After many failures, medicine finally succeeded biologically.

Antibody therapies now visibly clear amyloid on brain scans. The EMERGE and ENGAGE trials of Aducanumab showed plaque removal but inconsistent clinical benefit, leading to controversial approval based on biomarker change rather than functional improvement. The CLARITY-AD trial of Lecanemab, published in The New England Journal of Medicine in 2022, showed a statistically significant slowing of decline by about 27 percent, yet the difference in daily life remained modest. The TRAILBLAZER-ALZ 2 trial of Donanemab, published in JAMA in 2023, reported similar results. For families, the outcome felt confusing. The scans improved clearly. Life improved only slightly.

Researchers eventually understood why. Long-term biomarker studies summarized in Lancet Neurology show Alzheimer’s disease begins 15 to 20 years before forgetfulness appears. By the time treatment starts, large parts of the brain network are already lost. Removing plaques changes biology, but it cannot restore neurons that have already died. The treatment works. It simply arrives too late.

Parkinson’s disease, which involves degeneration of dopamine neurons, taught the same lesson. Scientists hoped that protecting these cells would slow progression. In animals, the strategy repeatedly succeeded. In patients, it did not work.

The PRECEPT trial testing CEP-1347 showed no disease-modifying benefit. The STEADY-PD III trial of Isradipine, published in The New England Journal of Medicine in 2020, confirmed that a drug protective in laboratory models did not prevent disability in humans. More recently, anti-alpha-synuclein antibody trials such as PASADENA and PADOVA demonstrated target engagement but failed to produce meaningful clinical improvement.

Pathology studies had already hinted at the explanation. By the time tremor appears, roughly half of substantia nigra dopamine neurons and most striatal dopamine are already lost. A drug cannot protect cells that no longer exist.

The disease begins long before diagnosis

In laboratory models, disease is fast and clear. Toxin damages neurons within days. A mutation produces symptoms within months. Cause and effect are visible. Human neurodegeneration behaves differently. It resembles slow aging under a microscope. Sleep disruption, inflammation, metabolism, environmental exposure, and genetics interact quietly for decades before symptoms appear. By the time someone notices tremor or memory loss, the brain has been compensating for injury for years. Many drugs were designed for early disease but tested in late disease. The medicine did not necessarily fail. The timing did.

One name, many diseases

Another discovery of a further complicated treatment. Alzheimer’s disease and Parkinson’s disease are not single, uniform disorders. Research in Nature Reviews Neurology and Neuron shows multiple biological subtypes involving inflammation, mitochondrial dysfunction, vascular injury, and immune signaling. Parkinson’s may even begin in the gut in some patients and in the brain in others.

Two patients may look identical in clinics but have different underlying biology. When placed in the same clinical trial, a drug helping one subgroup can appear ineffective overall. Cancer treatment improved only after medical science accepted that one diagnosis could contain many diseases. Neurology is now learning the same lesson.

Why this matters even more in Nepal

The gap between discovery and benefit becomes wider in countries like Nepal. As life expectancy rises, dementia and Parkinson’s disease are increasing. Early symptoms such as loss of smell, constipation, sleep disturbance, or slowed movement are often dismissed as normal aging. Medical care is usually sought only after tremors, falls, or major memory problems appear, indicating that the disease has already advanced. At such a stage, treatments designed to slow early degeneration can do little. Scientific progress exists globally, but its impact depends on timing. The challenge is not only access to medicine, but access early enough for medicine to matter.

Why failed trials still move science forward

A failed clinical trial sounds discouraging, but it rarely means the idea was wrong. Often, it means the treatment was given too late, to the wrong subgroup, or measured over too short a period. Because of these lessons, neuroscience is changing direction. Blood biomarkers, imaging, and genetic screening are being developed to detect disease years before symptoms appear. Prevention trials such as AHEAD 3-45 and DIAN-TU now test therapies in people who are biologically positive but still healthy. The central question is shifting from "Does the drug work? To whom should it be administered, and when?”

The real meaning of progress

For families living with brain disease, progress feels painfully slow. Yet decades of disappointing trials revealed something profound: these illnesses begin long before diagnosis. Many treatments did not fail because hope was misplaced. They failed because they met the disease at the wrong moment. The future of brain medicine may depend less on discovering a miracle cure and more on matching the right therapy to the right person at the right stage. When early detection, precise diagnosis, and timely treatment finally align, scientific breakthroughs will stop fading after headlines and begin changing everyday life both around the world and in Nepal.

The author is a PhD candidate in the Department of Neurosciences and Neurological Disorders at the University of Toledo

At a neonatal ward in Kathmandu, a doctor studies retinal images from a premature baby. To most people, the images look ordinary. To that doctor, they carry the weight of a lifetime. If early signs of abnormal brain and blood vessel development are missed, the child may grow up with permanent vision loss, learning difficulties, or both. In Nepal, where trained specialists are few and unevenly distributed, such decisions are often made under intense pressure, with limited support and little room for error. This is exactly where artificial intelligence should no longer be treated as a futuristic luxury, but as a public health necessity.

Artificial intelligence is already reshaping how neuroscience is practiced around the world. The real question for Nepal is not whether AI belongs in brain and neurological care, but whether we are willing to adopt it thoughtfully or allow preventable disability to continue simply because systems have not evolved.

At its core, neuroscience is about understanding how the brain develops, adapts, and sometimes fails. Artificial intelligence, on the other hand, is built to recognize patterns in vast and complex information. When these two fields come together, AI does not replace doctors or neuroscientists. Instead, it acts as a powerful assistant, helping humans see patterns that are difficult to detect consistently, especially when time, expertise, or resources are limited. For a country like Nepal, this partnership is not optional. It is strategic, practical, and necessary.

The evidence for this is no longer theoretical. A study published in Ophthalmology Science evaluated a deep learning system used to screen premature infants in Nepal for retinopathy of prematurity. The system performed with near-perfect accuracy, achieving an area-under-the-curve value of 0.999, using retinal imaging devices already available in Nepali hospitals. This was not an experiment in a high-income country with ideal conditions. It was tested in real hospitals, with real patients, and real constraints. The researchers concluded that AI could dramatically expand screening capacity, reduce pressure on scarce specialists, and enable earlier interventions, where delays often cost children in their futures.

This matters because retinopathy of prematurity is not just an eye disease. It reflects disrupted development of the brain’s blood vessels during a critical window of early life. Preventing severe disease is not only about saving vision; it is about protecting long-term neurological development. When artificial intelligence can reliably identify subtle warning signs earlier than the human eye, choosing not to use it becomes more than a missed opportunity. It raises serious ethical concerns.

The stakes extend far beyond neonatal care. Nepal is undergoing a demographic and epidemiological transition. As deaths from infectious diseases decline and life expectancy increases, neurological and mental health conditions are becoming more common. Conditions such as stroke, dementia, epilepsy, depression, and Parkinson’s disease now account for a growing share of disability. Data from the Global Burden of Disease study make this trend clear. Yet neurologists, psychiatrists, and advanced diagnostic facilities remain concentrated in a few urban centers. Expecting this system to meet future demand without technological support is simply unrealistic.

Public health researchers writing in the Nepal Journal of Epidemiology have pointed out that artificial intelligence could help improve diagnosis, predict risk, and guide population-level planning. But they also offer important warnings. If Nepal relies entirely on imported algorithms trained on foreign populations, it risks reinforcing inequity rather than reducing it. Health data reflect genetics, language, culture, and environment. AI tools must be validated locally, governed ethically, and paired with investment in Nepali expertise, not treated as black boxes delivered from abroad.

Encouragingly, Nepali scholars themselves have emphasized this balance. A 2025 article in the Journal of Universal College of Medical Sciences compared artificial intelligence and human brain function from a physiological perspective. Their conclusion was refreshingly grounded. AI is faster and more precise when handling large amounts of data. Humans remain superior in judgment, ethics, emotional understanding, and contextual decision-making. In healthcare, the goal is not competition, but collaboration. Machines should manage repetitive and data-heavy tasks so clinicians can focus on care, compassion, and responsibility.

Still, enthusiasm without caution is dangerous. Generative AI tools are now entering medical education and research, including in Nepal. A 2024 review in the Journal of Institute of Medicine Nepal highlighted both their promise and their risks. Issues such as data privacy, security, and confidently incorrect outputs are real concerns, particularly when dealing with sensitive brain and health information. These tools are powerful, but without training and oversight, they can mislead just as easily as they can assist. This is why education matters as much as technology. Studies on AI adoption in Nepal show that while awareness is increasing, access and digital literacy remain uneven, especially outside major cities. If clinicians are expected to rely on AI tools without understanding their strengths and limitations, the result will be mistrust or misuse.

Nepal now stands at a crossroads. Artificial intelligence in neuroscience is no longer a distant idea discussed only in conferences and journals. It is already helping detect disease earlier, analyze complex brain data, and support clinical decisions in resource-limited settings. The real danger lies not in adopting AI, but in doing so passively, without local data, ethical safeguards, and human oversight. The path forward is clear. Nepal must invest in digital health infrastructure, encourage collaboration between engineers, clinicians, and neuroscientists, and develop national guidelines that place ethics and equity at the center of AI use. Artificial intelligence should be treated as a public good, not a private experiment or a marketing slogan.

Used wisely, AI can help a general doctor in a district hospital recognize a neurological emergency before it is too late. It can help a premature child avoid a lifetime of preventable disability. Choosing not to act is itself a decision, one that disproportionately harms those with the least access to care. The future of neuroscience in Nepal will not be written by machines alone. It will be shaped by whether we choose to use these tools responsibly, locally, and humanely. The technology is ready. The evidence is strong. What remains is the collective will to act.

The author is a PhD candidate in the Department of Neurosciences and Neurological Disorders at the University of Toledo

In Nepal, stress has become so normal that we rarely pause to question it. Students grow up believing pressure is the price of success. Families live with unemployment, rising costs, and years of separation brought on by labor migration. Women quietly hold households together, caring for children and elders, stretching limited resources, and carrying responsibilities that leave little room for rest. When life feels too heavy, we often sigh, “yo ta sabai ko jindagi ho,” as if suffering is simply part of being alive.

Yet this quiet acceptance comes at a cost we seldom notice. When stress lasts for months or years, it does not remain confined to our thoughts or emotions. Gradually, it reshapes the brain itself, altering how we think, feel, and navigate daily life.

To understand this, it helps to know how the body is meant to handle stress. Our brains are built to withstand short periods of pressure. When danger arises, the brain releases cortisol, a hormone that sharpens our alertness and reaction. For a brief time, this response is helpful. Problems begin when worry, uncertainty, and pressure never cease. Cortisol levels stay elevated, and what once helped us starts to harm us.

Research shows that over time, prolonged stress weakens the hippocampus, the brain’s center for memory and learning. This explains why so many people complain of forgetfulness, mental fatigue, and trouble concentrating. They are not careless or lazy; their brains are simply worn down.

As stress continues, it also impairs the prefrontal cortex, which helps us think clearly, plan ahead, and regulate emotions. When this region is under sustained pressure, even simple tasks become difficult—small problems feel overwhelming, patience shortens, self-confidence erodes.

At the same time, stress strengthens the amygdala, the brain’s fear center. The mind remains on high alert, as though danger is ever-present. This makes it hard to relax, to sleep deeply, or to feel safe even at home. Living in this state for years increases the risk of anxiety, depression, substance use, and thoughts of self-harm.

Nepal’s mental health landscape reflects this reality. Millions are believed to be living with mental health conditions, with depression and anxiety among the most common. Many adults report suicidal thoughts. These are not mere statistics; they represent real people enduring long-term pressure, uncertainty, and silent struggle.

Still, we often misinterpret what we see. A student who cannot focus is called undisciplined. A migrant worker’s sadness is dismissed as part of the sacrifice. A woman’s exhaustion is accepted as her duty. Instead of asking what pressures people face, we wonder why they are not stronger.

This perspective is especially damaging in a country where mental health care remains difficult to access and stigma runs deep. Many suffer in silence, believing their pain is a personal failure rather than a natural response to sustained stress. They blame themselves for struggles shaped by social and economic forces far beyond their control.

There is, however, reason for hope. The brain is not fixed; it can heal. Rest, movement, supportive relationships, and feeling understood all help calm the nervous system. Even small moments of safety and connection matter. They signal to the brain that it is finally safe to slow down.

Yet personal coping has its limits. No breathing exercise can replace stable work. No meditation can reunite families after years apart. No positive thinking can undo systemic inequality. If stress is quietly altering our mind, it must be treated as a public health and social issue, and not as a personal shortcoming.

Viewing stress in this way changes how we treat one another. It encourages kindness over judgment. It challenges the notion that silent suffering is strength. And it reminds us that mental health is not a luxury; it is essential for learning, productivity, family well-being, and the future of our society.

The brain responds to the world we build around it. The question is whether we are willing to change that world before the cost grows too great to ignore.